In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers (Basel).

Heeke S, Benzaquen J, Long-Mira E, Audelan B, Lespinet V, Bordone O, Lalvée S, Zahaf K, Poudenx M, Humbert O, Montaudié H, Dugourd PM, Chassang M, Passeron T, Delingette H, Marquette CH, Hofman V, Stenzinger A, Ilié M, Hofman P.

2019 Aug 29;11(9).

DNAshell Protects DNA Stored at Room Temperature for Downstream Next-Generation Sequencing Studies. Biopreserv Biobank.

Washetine K, Heeke S, Ribeyre C, Bourreau C, Normand C, Blons H, Laurent-Puig P, Mulot C, Clermont D, David M, Clément B, Dagher G, Hofman P.

2019 Aug;17(4):352-354.

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients. J Thorac Oncol.

Hofman V, Rouquette I, Long-Mira E, Piton N, Chamorey E, Heeke S, Vignaud JM, Yguel C, Mazières J, Lepage AL, Bibeau F, Begueret H, Lassalle S, Lalvée S, Zahaf K, Benzaquen J, Poudenx M, Marquette CH, Sabourin JC, Ilié M, Hofman P.

2019 Jul;14(7):1204-1212.

Companion diagnostic tests for treatment of lung cancer patients: what are the current and future challenges? Expert Rev Mol Diagn.

Hofman P, Barlesi F.

2019 May;19(5):429-438.

Tumor banks and complex data management: Current and future challenges. Ann Pathol.

Hofman P, Dagher G, Laurent-Puig P, Marquette CH, Barlesi F, Bibeau F, Clément B.

2019 Apr;39(2):137-143.

The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again. Cancers (Basel).

Hofman P, Ayache N, Barbry P, Barlaud M, Bel A, Blancou P, Checler F, Chevillard S, Cristofari G, Demory M, Esnault V, Falandry C, Gilson E, Guérin O, Glaichenhaus N, Guigay J, Ilié M, Mari B, Marquette CH, Paquis-Flucklinger V, Prate F, Saintigny P, Seitz-Polsky B, Skhiri T, Van Obberghen-Schilling E, Van Obberghen E, Yvan-Charvet L.

2019 Feb 21;11(2).

The age of artificial intelligence in lung cancer pathology: Between hope, gloom and perspectives. Ann Pathol.

Heeke S, Delingette H, Fanjat Y, Long-Mira E, Lassalle S, Hofman V, Benzaquen J, Marquette CH, Hofman P, Ilié M.

2019 Apr;39(2):130-136.

Lung Cancer Screening, Towards a Multidimensional Approach: Why and How? Cancers (Basel).

Benzaquen J, Boutros J, Marquette C, Delingette H, Hofman P.

 

2019 Feb 12;11(2).

Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time? Cancers (Basel).

Hofman P, Badoual C, Henderson F, Berland L, Hamila M, Long-Mira E, Lassalle S, Roussel H, Hofman V, Tartour E, Ilié M.

2019 Feb 27;11(3)

Circulating Tumor Cell Detection in Lung Cancer: But to What End?. Cancers (Basel).

Hofman V, Heeke S, Marquette CH, Ilié M, Hofman P.

2019 Feb 23;11(2)

Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients. Lung Cancer.

Falk AT, Yazbeck N, Guibert N, Chamorey E, Paquet A, Ribeyre L, Bence C, Zahaf K, Leroy S, Marquette CH, Cohen C, Mograbi B, Mazières J, Hofman V, Brest P, Hofman P, Ilié M. 

2018 Jul;121:70-75.

Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA. Cancers (Basel).

Washetine K, Kara-Borni M, Heeke S, Bonnetaud C, Félix JM, Ribeyre L, Bence C, Ilié M, Bordone O, Pedro M, Maitre P, Tanga V, Gormally E, Mossuz P, Lorimier P, Marquette CH, Mouroux J, Cohen C, Lassalle S, Long-Mira E, Clément B, Dagher G, Hofman V, Hofman P. 

2018 Jun 11;10(6).

Use of circulating tumor cells in prospective clinical trials for NSCLC patients - standardization of the pre-analytical conditions. Clin Chem Lab Med.

Ilie M, Hofman V, Leroy S, Cohen C, Heeke S, Cattet F, Bence C, Lalvée S, Mouroux J, Marquette CH, Hofman P; STALKLUNG01 and AIR Study Consortium Investigators.

2018 May 24;56(6):980-989.

Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients. Cancers (Basel).

Heeke S, Hofman V, Long-Mira E, Lespinet V, Lalvée S, Bordone O, Ribeyre C, Tanga V, Benzaquen J, Leroy S, Cohen C, Mouroux J, Marquette CH, Ilié M, Hofman P. 

2018 Mar 21;10(4).

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? Cancers (Basel).

Hofman V, Lassalle S, Bence C, Long-Mira E, Nahon-Estève S, Heeke S, Lespinet-Fabre V, Butori C, Ilié M, Hofman P. 

2018 Mar 13;10(3).

Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Annals of Oncology

Ilié M, Szafer-Glusman E, Hofman V, Chamorey E, Lalvée S, Selva E, Leroy S, Marquette CH, Kowanetz M, Hedge P, Punnoose E, Hofman P.

2018 Jan 1;29(1):193-199.

PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted? Expert Rev Mol Diagn. 

Hofman P. 

2017 Dec;17(12):1097-1108

Training the Next Generation of Biobankers: A Two-Year Master ’s Course in the Management of Biobanks.  Biopreservation and Biobanking

Gormally E, Hardy I, Caboux E, di Donato JH, Hainaut P, Hofman P. 

2017 Oct;15(5):438-450

Optimization of EGFR mutation detection by the fully-automated PCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. Oncotarget.

Ilie M, Butori C, Lassalle S, Heeke S, Piton N, Sabourin JC, Tanga V, Washetine K, Long-Mira E, Maitre P, Yazbeck N, Bordone O, Lespinet V, Leroy S, Cohen C, Mouroux J, Marquette CH, Hofman V, Hofman P. 

2017 Oct 4;8(61):103055-103062